12 May, 2026 New Analyses from Vutrisiran Program Presented at Heart Failure 2026
Posted at 02:30h
in
Capella
by Chris Brickley
Analyses presented at Heart Failure 2026 reinforce the consistent clinical profile of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), including across clinically complex populations with a high disease burden and in the context of concomitant therapies. Additional data further characterize transthyretin (TTR) knockdown and support its relevance in real-world clinical practice.
A pooled safety analysis evaluating vitamin A-related outcomes across clinical trial and real-world datasets shows no evidence of clinically meaningful safety concerns associated with TTR reduction. The design of DemonsTTRate, a global, long-term observational study evaluating real-world use of vutrisiran in ATTR-CM, was also presented.
Abovich, et al. “Influence of Disease-Modifying Therapy on the Effectiveness of Vutrisiran in Transthyretin Cardiac Amyloidosis”
Birkhoelzer, et al. “Comorbidity Burden in Transthyretin Amyloidosis With Cardiomyopathy: Insights From the HELIOS-B Trial”
Mansell, et al. “Consistent Efficacy of Vutrisiran Across Sexes in ATTR-CM, HELIOS-B Trial – Prespecified Sex Analysis”
Sheikh, et al. “Influence of Vutrisiran on Systolic Blood Pressure in ATTR-CM: Insights From HELIOS-B”
Wang, et al. “Effect of Vutrisiran in Patients with and without Atrial Fibrillation or Flutter: Analysis from HELIOS-B”
Algalarrondo, et al. “Vutrisiran-Mediated Knockdown of Transthyretin in Patients with Transthyretin Amyloidosis”
Maurer, et al. “Treatment with Transthyretin-Lowering RNA Interference Therapeutics is Not Associated with Ocular or Other Clinical Events Due to Vitamin A Reduction: Pooled Analysis of Vutrisiran and Patisiran Data”
Garcia-Pavia, et al. “Design and Rationale of DemonsTTRate: A Global, Long-Term Observational Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy”
